|Bid||22.90 x 800|
|Ask||23.50 x 900|
|Day's Range||21.85 - 22.96|
|52 Week Range||21.38 - 42.00|
|Beta (3Y Monthly)||0.93|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 13, 2017 - Nov 17, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||55.00|
Aimmune Therapeutics, Inc. (AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the appointment of Andrew Oxtoby as Chief Commercial Officer. Mr. Oxtoby, a proven pharmaceutical executive with two decades of experience in the healthcare and consumer products industries, will join Aimmune in the newly created role on Tuesday, January 22. “Andrew has a terrific track record of accomplishment in leading U.S. and global commercial organizations to successfully launch novel medicines and build innovative patient solutions in large disease areas, which will be tremendously valuable to Aimmune as we prepare to address the emerging food allergy therapeutic space,” said Jayson Dallas, M.D., Aimmune President and CEO.
NEW YORK, NY / ACCESSWIRE / January 15, 2019 / Wall Street extended losses on Monday as concerns of a global economic slowdown were reignited on weaker-than-expected economic data from China. In December, ...
On CNBC's "Mad Money Lightning Round" , Jim Cramer said Dynavax Technologies Corporation (NASDAQ: DVAX ) is too low to sell, but he doesn't have a catalyst. Instead of ArcelorMittal SA (NYSE: ...
In my approach to the stock market, strategy is far more important than prediction. My favorite stock for 2019 is Aimmune Therapeutics, Inc. Aimmune is a biotechnology company focused on developing products for the treatment of peanut and food allergies using a desensitization approach.
Aimmune Therapeutics, Inc. (AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it has entered into a $170 million loan agreement with an affiliate of KKR, a leading global investment firm. “The addition of the KKR loan financing to Aimmune’s capital resources is expected to fully fund the commercialization of AR101, an investigational biologic oral immunotherapy for the treatment of peanut allergy,” said Eric Bjerkholt, Chief Financial Officer of Aimmune Therapeutics.
NEW YORK, Jan. 03, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Aimmune Therapeutics, Inc. (AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that CEO Jayson Dallas, M.D., will present a company overview at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 7, 2019, at 3:00 p.m. Pacific Time. Dr. Dallas will highlight recent progress, including the submission of a Biologics License Application to the U.S. Food and Drug Administration for AR101 in peanut allergy (ages 4-17), and provide an outlook for key milestones expected in 2019, including potential approval and launch of AR101 in the United States and planned filing for marketing approval in Europe. A live audio webcast of the presentation and Question and Answer session will be accessible from the Investor Relations section of the Aimmune Therapeutics website at www.aimmune.com.
Aimmune Therapeutics, Inc. (AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for AR101, an investigational biologic oral immunotherapy for the treatment of peanut allergy in children and adolescents ages 4–17. The FDA granted AR101 Fast Track Designation for peanut allergy in September 2014 and Breakthrough Therapy Designation for peanut allergy in ages 4–17 in June 2015. “The submission of the BLA represents a significant milestone for Aimmune and the food allergy community, for whom there currently are no approved treatments,” said Jayson Dallas, M.D., President and CEO of Aimmune.
CORAL GABLES, FL / ACCESSWIRE / December 20, 2018 / The biotech industry is predicated on the notion that, presently, we can do more to create better treatment options and medical technologies to improve the quality of care for those suffering from a myriad of ailments. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Fennec Pharmaceuticals, Inc (FENC), Aimmune Therapeutics, Inc (AIMT), and Kezar Life Sciences, Inc (KZR) are 4 biotech stocks representing companies working towards the advancement of the biotech sector. Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company ready to meet the demands of consumers looking for access to quality primary care.
(Bloomberg) -- DBV Technologies SA lost two-thirds of its market value after it withdrew a U.S. application for a peanut allergy patch for children, shocking investors and prompting at least four analysts to downgrade the stock.
DBV said Wednesday after the close it has voluntarily withdrawn its Biologic License Application, or BLA, for Viaskin Peanut in children 4-11. The decision to withdraw the application was made at the behest of the FDA, which communicated its decision orally and in writing Dec. 18. Reacting to the development, Bank of America Merrill Lynch analyst Tazeen Ahmad downgraded DBV from Buy to Underperform and reduced the price target from $30 to $8.
Aimmune Therapeutics, Inc. (AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the submission of its investigational new drug (IND) application for AR201 for the treatment of egg allergy. The company also announced an exclusive supply agreement for egg protein with Michael Foods, Inc., the largest U.S. processor of value-added eggs. Aimmune expects to initiate a Phase 2 clinical trial of AR201 for the treatment of egg allergy in 2019.
NEW YORK, NY / ACCESSWIRE / December 20, 2018 / U.S. equities closed down on Wednesday as the anticipated interest rate increase was confirmed by the Federal Reserve, following Chairman Jerome Powell’s ...
Nasdaq-listed shares of DBV Technologies fell almost 50% in after hours trading on Wednesday as the French company withdrew an FDA application for its lead product candidate.
Aimmune Therapeutics, Inc. (AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it has initiated POSEIDON (Peanut Oral Immunotherapy Study of Early Intervention for Desensitization), an international, Phase 3 clinical trial of AR101 in peanut-allergic children ages 1–3 years. AR101 is Aimmune’s investigational biologic oral immunotherapy for desensitization of patients with peanut allergy.
Aimmune Therapeutics, Inc. (AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it will host an Investor Symposium in New York City on December 12, 2018. Aimmune’s senior management will discuss AR101’s clinical profile in peanut-allergic patients and the company’s preparations for a potential 2019 U.S. commercial launch. The event will also bring together leading expert allergists to discuss the emerging treatment landscape in peanut allergy, including the recent New England Journal of Medicine1 publication of the landmark PALISADE trial of AR101, the largest and only successful phase 3 peanut allergy immunotherapy trial to date.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 29) Allakos Inc (NASDAQ: ALLK ) Emergent Biosolutions Inc ...
Aimmune Therapeutics, Inc. (AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the closing of the $98 million equity investment by Nestlé Health Science. The sale of shares was made pursuant to the terms of the Securities Purchase Agreement entered into on November 11, 2018, by Aimmune and Nestlé Health Science, as previously reported by Aimmune. Additional details regarding the equity investment and strategic collaboration agreement can be found in Aimmune’s Form 8-K filed with the Securities and Exchange Commission on November 13, 2018.
NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Why a South Bay company thinks it can disrupt a tough antibiotics market — and more in our weekly Health Care Digest.
Aimmune Therapeutics fell as investors digested a study testing its oral immunotherapy in children with life-threatening peanut allergies. Aimmune stock lost more than 7% by midday.
The key takeaway: After a year of treatment, two-thirds of children who took the medication were able to eat small amounts of peanuts. This isn’t a cure. But it has a shot at U.S. government approval, and could make the lives of children with few options easier and safer. Instead, Aimmune has taken a pre-existing method of allergy protection — carefully exposing children to de-fatted peanut flour to desensitize them — and finely tuned it in an effort to pass muster with the Food and Drug Administration. Aimmune produces capsules or sachets with a precise quantity of its drug, which is then mixed into food. The study showed that this can be highly effective for many children. Being able to eat a peanut or two may not permit a change in diet, but the treatment offers protection against potentially deadly accidental exposure and a path toward a less regimented and fearful lifestyle. That’s no small achievement, given that peanut allergies have become increasingly common in America.